'Prostate cancer market leader' Astellas eyes on KRW 300 bil
By Hwang, Byung-woo | translator Kang, Shin-Kook
24.07.19 05:00:52
가나다라
0
Sales in 2019·2020·2021·2022, KRW 290 bil·KRW 275.6 bil·KRW 246.2 bil·KRW 232.2 'declining sales curve'
Prostate cancer drug Xtandi generated KRW 43.2 billion in sales, and Prograf leads the company in sales with KRW 91.4 billion
Xospata's sales are expected to increase after expanded reimbursement…the possibility of Padcev becoming reimbursement listed could potentially drive new sales growth
Astellas Pharma Korea's sales rebounded within four years due to the sales growth of Xtandi (enzalutamide), a prostate cancer drug.
In addition to its leading product, Prograf (tacrolimus), showing strong sales, the company is expected to continue to generate sales growth when Padcev (enfortumab vedotin), an ADC for the treatment of urothelial cancer, become reimbursable.
▲Product photo of Xtandi
After sales peaked at KRW 290 billion in 2019, Astellas Pharma Korea experienced a decline to KRW 232.2 billion in 2022
Last year, Astellas Pharma Korea's sales amounted to KRW 251. 1 billion, up 7.5% from KRW 232. 2 billion in 2022. This marks a rebound within 4 years after 2019.
Hwang, Byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)